Baudax Bio (NASDAQ: BXRX), a pharmaceutical Company developing novel therapeutics for Acute Care Settings, announed the approval of a New Drug Application ( NDA) for ANJESO (meloxicam injection), intended for alleviating moderate to severe pain, either as a standalone treatment or in combination with other...
Enlivex Therapeutics (NASDAQ: ENLV), a Company focused on developing allogenic therapies for immune system rebalancing, announced positive interim efficacy data from its ongoing Phase Ib clinical trial in patients with severe sepsis. The analysis in based on data collated from 43 patients with severe sepsis,...
Cyclerion Therapeutics (NASDAQ: CYCN), a clinical-stage Company, announced the failure of its drug candidate praliciguat in meeting the primary endpoints in two separate clinical studies, in diabetic nephropathy (DN) and heart failure with preserved ejection fraction (HFpEF). Praliciguat is a soluble guanylate cyclase (sGC) stimulator...
Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig’s disease is a progressive neurodegenerative disease, characterized by the atrophy of nerve cells in brain and spinal cord, leading to hardening and scarring in the affected region. As the disease progresses, patients gradually lose the functioning of muscles,...
Pompe disease is characterized by the build-up of complex sugars named glycogens in the body’s cell, due to the lack of an enzyme called acid alfa glucosidase (GAA), which is responsible for breaking down the sugars. This results in the breakdown of organs, muscles and...
The U.S Healthcare system is estimated to be a $3.2 trillion market comprising of various stakeholders such as hospitals, insurance companies, medical equipment suppliers and pharmacies to name a few. The world is moving towards digitization at a fast pace, and healthcare is one industry...
Otonomy Inc (NASDAQ: OTIC), a biopharmaceutical company focussed on providing neurotology solutions, announced a strategic collaboration with Applied Genetic Technologies Corporation (NASDAQ: AGTC), a biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, to create, develop and commercialize an AAV-based...
Menlo Therapeutics (NASDAQ: MNLO), a late-stage biopharmaceutical company, has announced the completion of enrollment of patients in a crucial phase 2 clinical trial for studying the efficacy and safety of once daily oral serlopitant for the treatment of Chronic Pruritus (itch) of Unknown Origin (CPUO)....
Nonalcoholic Steatohepatitis (NASH) is a form of Non-Alcoholic Fatty Liver Disease (NAFLD) and is characterized by the buildup of FAT in the liver. This condition is marked by hepatitis, inflammation, cell damage and fat deposits in the liver. These fat deposits can cause fibrosis of...
CytoDyn Inc (OTCQB: CYDY), a clinical stage biotechnology company, announced the filing of an Investigational Drug License (IND) for treatment of NASH with Leronlimab. The drug candidate is a humanized IgG4 mAb CCR5 antagonist that has been granted the Fast Track designation by the FDA...
